High Income DIY Portfolios: The primary goal of "High Income DIY Portfolios" Marketplace service is high income with low risk and preservation of capital. It provides DIY investors with vital information and portfolio/asset allocation strategies to help create stable, long-term passive income with sustainable yields. The portfolios are designed for Income-Investors (including retirees or near-retirees). We provide seven portfolios: 3 buy-and-hold, 3 Rotational portfolios, and 3-Bucket NPP Model Portfolio. T ...

【深圳商报讯】(记者刘娥)我国生物医用材料领域取得重大突破。近期，由深圳华诺生物科技有限公司 自主研发的"可吸收止血流体凝胶"获得国家药品监督管理局(NMPA)三类医疗器械注册证，成功打破美 国强生公司在该高端止血耗材领域长达10年的市场垄断。华诺生物科技创始人，大连理工大学教授、博 导王华楠表示，截至目前，该产品已实现近千家医院入院，预计到2026年将实现强生产品30%—40%的 市场替代，未来5年完成全面替代。 这一突破性成果源自王华楠团队17年的持续研发。与传统材料依赖稳定的共价键不同，华诺生物创新 的"自愈合分子技术"基于"动态非共价键"原理，使材料在被破坏后能够快速重组恢复结构和强度。该技 术同时具备了流体的可注射性和固体的支撑能力，在微创手术中，医生可以通过腹腔镜将材料精准注入 体内深处出血点，实现快速止血封闭。 业内专家指出，随着国家加大对高端医疗器械产业的支持力度，未来5—10年将是中国医疗器械耗材企 业集中爆发期。华诺生物的成功案例表明，通过产学研深度融合，中国企业在高端医疗耗材领域完全有 能力突破技术壁垒，实现从跟跑到并跑甚至领跑的跨越。 目前，华诺生物已与多家国际机构开展合作，其自主研发 ...

Core Perspective - The government is shifting its focus towards railway safety, with a modest increase in spending for FY26 [1] Group 1: Government Spending - The outlay for railway safety increased by only 2% in FY26 [1] - Historically, railway capital and revenue spending on safety has accounted for approximately 20% of the total budget [1] Group 2: Recent Incidents - The renewed focus on safety follows a train collision in Bilaspur, Chhattisgarh, which resulted in 11 fatalities and around 20 injuries [1]

Core Insights - Johnson & Johnson (J&J) has a strong R&D pipeline focused on immunology, oncology, and neuroscience, with significant advancements in 2025 [1][2][8] Pipeline and Product Approvals - J&J has achieved major clinical and regulatory milestones, including approvals for Inlexzoh/TAR-200 for high-risk non-muscle invasive bladder cancer and Imaavy (nipocalimab) for generalized myasthenia gravis [2][11] - Nipocalimab is being evaluated for various immune-mediated conditions and is considered to have pipeline-in-a-product potential [3] - Regulatory applications for icotrokinra, an oral treatment for moderate-to-severe plaque psoriasis, have been filed in the US and EU [4] - J&J's new cancer drugs, including Carvykti, Tecvayli, and Talvey, generated $2.14 billion in sales in the first nine months of 2025 [5][11] Strategic Acquisitions and Expansions - The acquisition of Intra-Cellular Therapies added Caplyta, an antidepressant, to J&J's neuroscience portfolio [6] - J&J aims to expand the indications of currently marketed products, with recent approvals for Tremfya, Rybrevant, and Caplyta [7] Long-term Growth Potential - J&J's pipeline execution and recent product approvals position the company for sustained growth beyond short-term pressures, with multiple late-stage assets and significant sales potential across its Innovative Medicine portfolio [8] Competitive Landscape - J&J faces competition in the oncology space from major players like Pfizer, AstraZeneca, Merck, and Bristol-Myers, each with strong oncology portfolios and growth in sales [9][10][12][13][14] Financial Performance and Valuation - J&J's shares have outperformed the industry, rising 42.8% over the past year compared to a 17.5% increase for the industry [15] - The company's shares trade at a price/earnings ratio of 18.09, slightly above the industry average of 17.59 and its five-year mean of 15.65 [18] - The Zacks Consensus Estimate for 2025 earnings has increased from $10.86 to $10.87 per share, indicating positive earnings revisions [20]

Johnson & Johnson said on Friday it has discontinued a mid-stage study of its experimental drug to treat patients with moderate to severe atopic dermatitis, after it failed to meet efficacy goals in a... ...

强生创新制药中国区总裁Cherry Huang女士表示，中国约40%的肺癌患者携带 EGFR 突变。此次获批具 有里程碑意义，进一步巩固了埃万妥单抗在 EGFR 突变非小细胞肺癌治疗中的重要地位。这一患者群 体存在巨大的未被满足医疗需求，而埃万妥单抗皮下注射制剂为患者和临床医生带来了更便捷的给药方 式和更好的耐受性，同时保持了良好的疗效与可控的安全性。 埃万妥单抗是一款全人源 EGFR×MET 双特异性抗体。埃万妥单抗皮下注射制剂含有重组人透明质酸酶 (rHuPH20)，使用 Halozyme 公司的 ENHANZE®给药技术，给药时间仅约5分钟，这一创新不仅有望提 升患者的生活质量，让他们有更多时间回归正常生活，也有助于优化医疗资源配置，推动中国医疗体系 的可持续发展。 智通财经APP获悉，12月25日，强生(JNJ.US)宣布，旗下创新治疗药物锐珂捷®——埃万妥单抗注射液 (皮下注射)正式获得中国 NMPA 批准，用于治疗携带表皮生长因子受体(EGFR)突变的晚期非小细胞肺 癌(NSCLC)患者。埃万妥单抗皮下注射制剂为患者提供了更高的便利性，将给药时间从数小时缩短至约 5分钟，同时相较于静脉注射制剂，其 ...

(文/解红娟 编辑/张广凯） 强生婴儿爽身粉再次被推上了舆论的风口浪尖。 据央视财经报道，当地时间22日，美国马里兰州一个陪审团裁定，美国强生公司需向因使用其婴儿爽身 粉产品而罹患癌症的一名女子，支付约15.6亿美元（约合人民币110亿元）赔偿。 据悉，这名女子指控强生公司的婴儿爽身粉产品含有石棉，导致她患上间皮瘤。而陪审团认为，强生公 司对未能警告原告其婴儿爽身粉含有石棉负有责任。 需要指出的是，这是强生公司有史以来单一原告获得的最高赔偿。对此，强生公司于23日表示将立即启 动上诉程序。 强生婴儿爽身粉的诞生最早可追溯至1890年。彼时，针对婴儿皮肤易受刺激、易生痱子等痛点，强生推 出全球首款婴儿专用爽身粉，核心定位是"温和呵护宝宝娇嫩肌肤"，强调产品采用天然滑石粉，能有效 吸收多余湿气，预防痱子与皮肤红肿。 出问题的正是其主要成分之一滑石粉。有研究显示，爽身粉原料滑石粉的矿藏常常位于含石棉矿藏附 近，滑石粉被开采时可能沾染石棉。而石棉被世界卫生组织国际癌症研究机构列为一类致癌物。 近年来，不少消费者指控如长期使用强生婴儿爽身粉和其他滑石粉产品后，不幸患上癌症，其中卵巢癌 和间皮瘤成为主要的指控病症。 早在 ...

Group 1 - The revised Public Security Administration Punishment Law will take effect on January 1, 2026, and has garnered significant attention from media and the public regarding Article 136 [4][5] - The law's revision process included public consultations during its initial and second readings in August 2023 and June 2024, respectively, with specific provisions for sealing records of minor offenders [5][6] Group 2 - The law's provisions for sealing public security violation records apply to minors, covering various types of violations [5] - The law aims to address public concerns and clarify the implications of sealing records for individuals involved in minor offenses [4][5] Group 3 - The law's revisions reflect a broader trend in legal reforms aimed at balancing public safety with the rehabilitation of young offenders [5][6] - The law's implementation is expected to influence public perception and legal practices surrounding juvenile offenses in China [4][5]

每经编辑｜张喜威 王晓波 ↓ 今日有3000亿元1年期MLF到期 2 2025粤港澳大湾区低空经济高质量发 于12月25日在广州举办 (3)第十六届物联网产业与智慧城市发展ʻ 12月25日举办 2 金融支持加快西部陆海新通道建设 八部门联合发布21条举措 近日，中国人民银行、国家发展改革委、财政部、交通运输部、商务部、金融监管总局、中国证监会、国家外汇局联合印发《关于金融支持加快西部陆海新 通道建设的意见》（以下简称《意见》）。《意见》从完善金融组织协作体系，构建高质量资金融通体系，推进制度性改革创新，建设数字金融服务平台， 完善金融开放合作体系，深化跨省跨境金融监管协作等方面提出21条重点举措，推动发挥好"融资"和"结算"两项金融核心功能，支持西部陆海新通道高质量 发展。（央视新闻） 1 隔夜市场 美股三大指数集体收涨，均录得日线5连涨，道指涨0.6%，标普500指数涨0.32%，纳指涨0.22%，其中，标普500指数、道指均创收盘历史新高；大型科技 股涨跌不一，苹果、微软、奈飞、亚马逊、Meta等小幅上涨；谷歌、英伟达、特斯拉、英特尔小幅下跌。纳斯达克中国金龙指数微跌0.07%，中概股涨跌不 一，知乎涨近 ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Johnson & Johnson.Looking at options history for Johnson & Johnson (NYSE:JNJ) we detected 11 trades.If we consider the specifics of each trade, it is accurate to state that 72% of the investors opened trades with bullish expectations and 0% with bearish.From the overall spotted trades, 4 are puts, for a total amount of $411,540 and 7, calls, for a total amount of $424,038.What's The Price Target?Analyzing the Volume and Open Inter ...